Contracts › 75N91023F00021
75N91023F00021: Drug Product Formulation Development, Gmp Manufacture, and Long-Term Stability Studies of Bitox for Phase I Clinical Trials
Awarded to Leidos Biomedical Research Inc by National Institutes of Health (NIH).
$1.6Mobligated
$1.6Mpotential value
14 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91023F00021 |
|---|---|
| Vehicle | 75N91019D00024 |
| Awardee | Leidos Biomedical Research Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | MD |
| Period of performance | 15 September 2023 to 14 September 2026 |
| Potential end | 14 September 2028 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record